Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS)

The World Health Organization, 2012 The World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization, 2011 Perk, 2012, Atherosclerosis, 223, 1, 10.1016/j.atherosclerosis.2012.05.007 Kotseva, 2009, EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries, Eur J Cardiovasc Prev Rehabil, 16, 121, 10.1097/HJR.0b013e3283294b1d The World Health Organization, 2011 The World Health Organization, 2011 The World Health Organization, 2011 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Deedwania, 2006, Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study, Lancet, 368, 919, 10.1016/S0140-6736(06)69292-1 Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X Cziraky, 2008, Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting, J Manag Care Pharm, 14, S3 Nesto, 2005, Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome, Am J Cardiovasc Drugs, 5, 379, 10.2165/00129784-200505060-00005 Leiter, 2011, Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study, Diabet Med, 28, 1343, 10.1111/j.1464-5491.2011.03360.x Kotseva, 2008, Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey, Atherosclerosis, 197, 710, 10.1016/j.atherosclerosis.2007.07.004 Sudano, 2011, Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients, Swiss Med Wkly, 141, w13200 Gitt, 2012, Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada, Eur J Prev Cardiol, 19, 221, 10.1177/1741826711400545 Gitt, 2010, Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany, Clin Res Cardiol, 99, 723, 10.1007/s00392-010-0177-z Goodman, 2010, Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS), Can J Cardiol, 26, e330, 10.1016/S0828-282X(10)70454-2 Horgan, 2011, Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS), Ir J Med Sci, 180, 343, 10.1007/s11845-011-0702-8 Catapano, 2011, ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis, 217, 3, 10.1016/j.atherosclerosis.2011.06.028 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Roberts, 1997, The rule of 5 and the rule of 7 in lipid-lowering by statin drugs, Am J Cardiol, 80, 106, 10.1016/S0002-9149(97)00298-1 Perk, 2012, Int J Behav Med, 19, 403, 10.1007/s12529-012-9242-5 Parzen, 1962, On estimation of a probability density function and mode, Ann Math Stat, 33, 1065, 10.1214/aoms/1177704472 da Silva, 2011, Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS), Rev Esp Cardiol, 30, 47 Gonzalez-Juanatey, 2011, Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study, Rev Esp Cardiol, 64, 286 Liberopoulos, 2012, Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece, Angiology, 63, 184, 10.1177/0003319711410226 Strang, 2010, Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey, Neth J Med, 68, 168 Pomerleau, 2001, Dietary beliefs in the Baltic republics, Public Health Nutr, 4, 217, 10.1079/PHN200056 Pomerleau, 2000, Physical inactivity in the Baltic countries, Prev Med, 31, 665, 10.1006/pmed.2000.0761 Pomerleau, 2000, Patterns of body weight in the Baltic Republics, Public Health Nutr, 3, 3, 10.1017/S1368980000000021 Pudule, 1999, Patterns of smoking in the Baltic Republics, J Epidemiol Community Health, 53, 277, 10.1136/jech.53.5.277 Ērglis, 2012, A population-based cross-sectional study of cardiovascular risk factor in Latvia, Medicina (Kaunas), 48, 310 Org, 2011, HYPEST study: profile of hypertensive patients in Estonia, BMC Cardiovasc Disord, 11, 55, 10.1186/1471-2261-11-55 Reklaitiene, 2012, Trends in prevalence, awareness, treatment, and control of hypertension, and the risk of mortality among middle-aged Lithuanian urban population in 1983–2009, BMC Cardiovasc Disord, 12, 68, 10.1186/1471-2261-12-68 Eglit, 2011, Prevalence of diabetes and impaired glucose regulation in Estonia, Diabet Med, 28, 504, 10.1111/j.1464-5491.2010.03218.x Bandgar, 2011, Managing dyslipidaemia: evolving role of combination therapy, J Indian Med Assoc, 109, 549 Ito, 2012, Dyslipidemia: management using optimal lipid-lowering therapy, Ann Pharmacother, 46, 1368, 10.1345/aph.1R127 Eber, 2012, Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II, Curr Med Res Opin, 28, 1447, 10.1185/03007995.2012.717919